DJIA 17,253.38 96.53 0.56%
NASDAQ 4,589.83 27.64 0.61%
S&P 500 2,009.72 8.15 0.41%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014

Sarepta Therapeutics stock has been whipsawed over the past year. Find out what's been the cause of its volatility and whether or not the stock can head higher.

George Soros Is Betting on This Risky Stock: Should You?

Sarepta Therapeutics is a clinical-stage biotechnology company seeking to gain approval for a potentially game-changing Duchenne muscular dystrophy drug called eteplirsen. Wall Street appears convinced that the drug is a winner, but scientists have been less optimistic. Here's why.

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian at Morgan Stanley Healthcare Conference (Transcrip

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian at Morgan Stanley Healthcare Conference (Transcript)

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Ebola Outbreak Strikes Africa: How We're Fighting Back

Multiple drugs and vaccines are in development.

4 Companies To Look At After WHO Ebola Consultation In Geneva

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog

Biotechs That Might Benefit From Ebola

See More Articles...